Table 1.

Predictors of good response to TCZ therapy in severe COVID-19. Apart from PaO2/FiO2 all parameters identified as predictors were measured on TCZ initiation day.

PredictorOR95%CIp value
LDH <447 U/l12.674.42-36.31<0.001
<70% of lungs involved in CT6.762.63-17.36<0.001
9-12 days from symptoms onset6.431.82-22.730.004
RR <20/min5.402.29-12.75<0.001
hs-TnI <26 ng/l4.801.55-14.810.006
BUN <22.2 mg/dl4.712.02-10.99<0.001
SpO2/FiO2 >1224.471.92-10.40<0.001
fibrinogen ≥490 mg/dl4.461.86-10.72<0.001
no history of asthma/COPD4.391.55-16.710.030
no history of atrial fibrillation4.201.23-14.330.022
baseline PaO2/FiO2 >200 mmHg4.041.59-10.270.003
25(OH)D3 ≥30 ng/ml3.981.40-11.280.009
age <65 years3.691.60-8.460.002
no history of ischaemic heart disease3.561.29-9.790.014
procalcitonin 0.06-0.12 ng/ml3.201.20-8.540.020
D-Dimer ≤1.28 µg/ml3.121.37-7.090.006
IL-6 47.4-137.0 pg/ml3.071.90-4.98<0.001
  • OR – odds ratio, 95%CI – 95% confidence interval, LDH – lactate dehydrogenase, RR – respiratory rate, hs-TnI – high sensitivity troponin I, BUN – blood urea nitrogen, COPD – chronic obstructive pulmonary disease, 25(OH)D3 – 25-hydroxycholecalciferol, IL-6 – interleukin 6